Idelalisib: A PI3K Inhibitor on the Horizon

Seema Bhat, MD, and Myron S.Czuczman, MD
Published Online: January 9, 2014
Seema Bhat, MD

Seema Bhat, MD

Assistant Professor of Oncology
Department of Medicine, Roswell Park Cancer Institute,
Buffalo, NY

Myron S.Czuczman, MD

Myron S.Czuczman, MD

Professor of Oncology
Chief, Lymphoma/Myeloma Service,
Department of Medicine, Roswell Park Cancer Institute,
Buffalo, NY


Idelalisib is a potent and highly selective PI3K inhibitor that promotes apoptosis in primary cells from patients with different B-cell malignancies. Idelalisib has been shown to affect microenvironmental signaling and cell survival both in vitro and in vivo. Data from studies with idelalisib have shown promising clinical efficacy, both as a single agent, as well as in combination with other agents. It is an orally active agent that has been shown to be well tolerated, with diarrhea and a transient increase in transaminases being the most common reported adverse effects. The FDA currently has a New Drug Application under review for use of idelalisib for the treatment of indolent non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western hemisphere. It is a clonal malignancy of mature B lymphocytes and is characterized by the accumulation of CD5+/ CD23+ monoclonal B cells in the blood and tissue compartments, including bone-marrow and secondary lymphatic tissues.1 However, at a genetic level, there is a difference between CLL cells present in different compartments: CLL cells in the blood compartment are resting cells with a gene expression profile akin to memory B cells,1 whereas CLL cells in the lymph node and bone marrow compartment show characteristics of activated B cells and exhibit increased proliferation.2 Moreover, the biology of CLL cells is influenced by extrinsic signals from the tissue microenvironment. In vitro, CLL cells cannot sustain themselves and undergo apoptosis unless appropriate microenvironmental factors are provided by co-culturing them with accessory stromal cells, like marrow stromal cells (MSCs)3 or monocyte-derived nurse-like cells (NLCs).4 This reliance of CLL cells on pathways that are also involved in promoting normal B-cell development, expansion, and survival 2,5- 8 indicates that these tumor cells are “addicted to the host,” constituting an instance of a novel model termed non-oncogene addiction.9

Related Articles
The FDA has expanded the approval of ibrutinib (Imbruvica) to include the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy and harbor a 17p deletion.
B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). NHLs are a heterogeneous group of more than 30 cancers of B lymphocytes and T lymphocytes.
Creating new treatment options for CLL, particularly for high-risk patient populations such as those with fludarabine-refractory disease or with 17p deletions, is the goal of an intense effort by clinical researchers and pharmaceutical companies.
JTT Articles
The Transformation of Treatment in CLL: A Q & A With Dr. William G. Wierda
Novel Treatment Options for T790M-Mutant Non-Small Cell Lung Cancer
External Resources

Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.